ERAS Stock Analysis: Buy, Sell, or Hold?
ERAS - Erasca, Inc. Common Stock
$15.05
-0.02 (-0.13%)
▼
5d:
+12.48%
30d:
+33.9%
90d:
+2.59%
BUY
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Smart Money Distribution
None View Scanner →
Strength: 7.7/10
Get Alerted When ERAS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ERAS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ERAS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ERAS is currently trading at $15.05, which is considered extended relative to its 30-day fair value range of $11.64 to $14.34.
Technical Outlook: Technically, ERAS is showing sideways momentum. Immediate support is located at $13.00, while resistance sits at $15.75.
Market Sentiment: ERAS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $21.00 (+39.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ERAS is showing sideways momentum. Immediate support is located at $13.00, while resistance sits at $15.75.
Market Sentiment: ERAS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $21.00 (+39.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$11.64 -
$14.34
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 39.5% below Wall St target ($21.00)
Trading Range Analysis
30-Day Trading Range
$11.64 -
$14.34
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$13.00
Resistance Level
$15.75
Current Trend
Sideways
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-26.19
Wall Street Target
$21.00
(+39.5%)
Share & Embed Analysis
Last updated: June 25, 2026 12:28 AM ET
Data refreshes hourly during market hours. Next update: 1:28 AM
Data refreshes hourly during market hours. Next update: 1:28 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ERAS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Ebun Garner
SELL
80000 shares
2026-04-01
Shannon Morris
SELL
20000 shares
2026-03-04
Ebun Garner
SELL
120000 shares
2026-01-07
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 57 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 58 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
Advanced ERAS Option Strategies
Professional options setups generated by AI based on today's ERAS price and gamma walls.
